Social Behavior – Page 17

FDA Limits Use of Invivyd’s COVID-19 Prophylactic as New Variants Dominate

1 year ago talkbio0Tagged authorization, COVID19 (disease), Emergency Situation, Immunocompromised Host, Invivyd, Pemgarda, United States Food and Drug Administration, Variant

Invivyd, COVID-19, Pemgarda, Emergency Use Authorization, FDA, Immunocompromised, Variants

Regeneron Secures EU Approval for Lymphoma Treatment Ordspono Following FDA Rejection

1 year ago talkbio0Tagged Antibodies, Bispecific, Approved, EU, Lymphoma, Odronextamab, Ordspono, Regeneron, Rejection (Psychology), United States Food and Drug Administration

Regeneron, EU approval, lymphoma, bispecific antibody, odronextamab, Ordspono, FDA rejection

FDA Approves Updated COVID-19 Vaccines from Pfizer and Moderna for Enhanced Protection

1 year ago talkbio0Tagged Approved, authorization, COVID19 (disease), Emergency Situation, Guidelines, JN.1, KP.2, Lineage, Moderna, Pfizer, Pfizer/, RNA, Messenger, United States Food and Drug Administration, Vaccination, Vaccines, Variant

COVID-19 vaccines, FDA approval, mRNA vaccines, Pfizer, Moderna, updated vaccines, KP.2 variant, JN.1 lineage, emergency use authorization, vaccination guidelines.

FDA Rejects Regeneron’s Blood Cancer Bispecific, Delaying Competition with J&J and Pfizer

1 year ago talkbio0Tagged Hematologic Neoplasms, J&J, Linvoseltamab, Multiple Myeloma, Pfizer, Regeneron, Rejection (Psychology), United States Food and Drug Administration

Regeneron, FDA rejection, blood cancer bispecific, linvoseltamab, multiple myeloma, J&J, Pfizer

BioMarin Appoints New R&D and Business Development Leaders

1 year ago talkbio0Tagged BioMarin, business career, development aspects, Fuchs, Greg Friberg, James, Leadership, R&D, Sabry

BioMarin, R&D, Business Development, Leadership, Greg Friberg, James Sabry, Hank Fuchs

FDA Delays Approval of Regeneron’s Multiple Myeloma Drug Due to Manufacturing Issues

1 year ago talkbio0Tagged Antibodies, Bispecific, Cancer Therapeutic Procedure, Linvoseltamab, Multiple Myeloma, Regeneron, Rejection (Psychology), United States Food and Drug Administration

Regeneron, linvoseltamab, multiple myeloma, FDA rejection, manufacturing issues, bispecific antibody, cancer treatment

Embracing Agility: Critical for the Role of QARA Professional

1 year ago talkbio0Tagged Access, Agility, AI, Artificial Intelligence, Communication, Diversity, Inclusion, Leadership, Market, professional occupation status, QARA, quality assurance, Regulatory Affairs, regulatory strategy, Technology

QARA Professional, Agility, Quality Assurance, Regulatory Affairs, Market Access, Innovative Therapeutic Solutions, AI, Technology, Regulatory Strategy, Leadership, Communication, Diversity, Inclusion.